Dickkopf1 Promotes Pulmonary Fibrosis upon Bleomycin-Induced Lung Injury

Eun-Ah Sung1, Min Hee Park1, Octavian Henegariu2

  • 1Department of Microbiology and Immunology, Virginia Commonwealth University School of Medicine, Richmond, Virginia; Massey Cancer Center, Virginia Commonwealth University School of Medicine, Richmond, Virginia.

Insights

Dickkopf1 (DKK1) promotes lung inflammation and fibrosis after bleomycin (BLM)-induced injury. Reducing DKK1 levels in mice or using DKK1 antibodies lessened these harmful fibrotic effects, highlighting DKK1 as a therapeutic target.

Area of Science:

  • Pulmonary Medicine
  • Immunology
  • Molecular Biology

Background:

  • Tissue repair and inflammation are crucial for homeostasis after injury.
  • Fibrosis involves abnormal extracellular matrix accumulation, notably collagen.
  • Dickkopf1 (DKK1), a Wnt antagonist, has an unclear role in lung injury models.

Purpose of the Study:

  • To investigate the role of Dickkopf1 (DKK1) in bleomycin (BLM)-induced lung injury and fibrosis.
  • To determine if DKK1 is a potential therapeutic target for pulmonary fibrosis.

Main Methods:

  • Assessed DKK1 protein expression in BLM-induced mouse lung injury and human fibrotic lung tissues.
  • Utilized Dkk1 hypomorphic doubleridge (Dkk1d/d) mice to study DKK1's function.
  • Administered DKK1 antibodies in BLM-induced lung injury model.
  • Measured immune cell infiltration, collagen deposition, TGF-β1, and α-SMA expression.

Main Results:

  • BLM-induced lung injury significantly increased DKK1 protein levels in mice and human tissues.
  • Reduced DKK1 expression in Dkk1d/d mice abrogated BLM-induced lung inflammation and fibrosis.
  • Decreased immune cell infiltration, collagen deposition, TGF-β1, and α-SMA were observed in Dkk1d/d mice.
  • DKK1 antibody treatment reduced lung inflammation and fibrosis post-BLM injury.

Conclusions:

  • DKK1 acts as a proinflammatory and profibrotic ligand in BLM-induced lung injury.
  • DKK1 significantly contributes to the development of lung inflammation and fibrosis.
  • DKK1 represents a promising molecular target for treating pulmonary inflammation and fibrosis.